Therapeutic Guide for mTOuRing through the Braided Kidney Cancer Genomic River.
expert_opinion · Level V
Where this comes from
- Record sourced from PubMed, PMID 26920890.
- Also identified by DOI 10.1158/1078-0432.CCR-16-0035 and PMC identifier 5431075.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
mTORC1 inhibitors were first approved for the use in metastatic kidney cancer. However, observed treatment benefit was highly heterogeneous among patients. Through case-based cancer genomic sequencing of therapeutic outliers, we can begin to appreciate the convergent evolution of given cancer pathways/phenotypes beyond genes in kidney cancer, like a braided river. Clin Cancer Res; 22(10); 2320-2. ©2016 AACRSee related article by Kwiatkowski et al., p. 2445.
Medical subject headings
- Antineoplastic Agents
- Kidney Neoplasms
- Protein Kinase Inhibitors
- TOR Serine-Threonine Kinases